Edition:
United States

Ignyta Inc (RXDX.OQ)

RXDX.OQ on NASDAQ Stock Exchange Capital Market

6.90USD
26 May 2017
Change (% chg)

$-0.15 (-2.13%)
Prev Close
$7.05
Open
$7.00
Day's High
$7.05
Day's Low
$6.70
Volume
60,695
Avg. Vol
107,813
52-wk High
$9.90
52-wk Low
$4.15

RXDX.OQ

Chart for RXDX.OQ

About

Ignyta, Inc. is a biotechnology company. The Company is focused on precision medicine in oncology. The Company is pursuing an integrated therapeutic (Rx) and companion diagnostic (Dx) strategy for treating cancer patients. The Company's pipeline includes various compounds, such as entrectinib, RXDX-105, taladegib and RXDX-106.... (more)

Overall

Beta: -0.95
Market Cap(Mil.): $374.92
Shares Outstanding(Mil.): 54.34
Dividend: --
Yield (%): --

Financials

  RXDX.OQ Industry Sector
P/E (TTM): -- 137.90 17.41
EPS (TTM): -2.90 -- --
ROI: -96.98 -8.48 -5.42
ROE: -138.82 -11.31 -4.68

BRIEF-FDA grants Ignyta breakthrough therapy designation for entrectinib

* Ignyta granted breakthrough therapy designation for entrectinib by U.S. Food and Drug Administration Source text for Eikon: Further company coverage:

May 15 2017

BRIEF-Ignyta prices offering of 12.5 mln shares at $6.15/share

* Ignyta announces pricing of public offering of common stock

May 04 2017

BRIEF-Ignyta announces proposed public offering of common stock

* Says offering 10.0 million common shares Source text for Eikon: Further company coverage:

May 02 2017

BRIEF-Ignyta Q1 loss per share $0.96

* Ignyta announces first quarter 2017 company highlights and financial results

May 01 2017

BRIEF-Ignyta updates progress towards NDA submissions

* Ignyta updates progress towards entrectinib dual trk and ros1 NDA submissions

Apr 27 2017

BRIEF-Ignyta announces peer-reviewed publication of activity of a TRK inhibitor

* Ignyta announces peer-reviewed publication of activity of a TRK inhibitor in a primary brain tumor: successful treatment of glioneuronal tumor with pan-TRK, CNS-active inhibitor Entrectinib published in precision oncology

Mar 30 2017

BRIEF-Ignyta to explore strategic options for Taladegib through amendment of Taladegib license agreement with Lilly

* Ignyta announces exploration of strategic options for Taladegib, enabled by amendment of Taladegib license agreement with Lilly

Mar 23 2017

BRIEF-Ignyta FY 2016 net loss $103.6 mln, or $2.69 per share

* Ignyta announces full year 2016 company highlights and financial results

Mar 14 2017

BRIEF-Ignyta's updated Phase 1 data on safety, anti-tumor activity published in Cancer Discovery

* Ignyta's updated Phase 1 data on safety, anti-tumor activity and CNS activity of entrectinib in cancers with TRK, ROS1 or ALK fusions published in Cancer Discovery

Feb 09 2017

More From Around the Web

Earnings vs. Estimates